NCT06120283 2026-04-15BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsBeOne MedicinesPhase 1 Recruiting399 enrolled
NCT06625775 2026-04-13Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1 Recruiting392 enrolled
NCT04579380 2025-12-19Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsSeagen Inc.Phase 2 Active not recruiting217 enrolled 19 charts
NCT06784193 2025-10-10Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsOlema Pharmaceuticals, Inc.Phase 1 Recruiting180 enrolled
NCT03169738 2025-02-21QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsImmunityBio, Inc.Phase 1/2 Withdrawn
NCT05905341 2023-11-08Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.PfizerPhase 1 Withdrawn
NCT01655225 2022-04-08A Study of LY3023414 in Participants With Advanced CancerEli Lilly and CompanyPhase 1 Completed156 enrolled